BIO3 Biotest AG Pfd

EQS-News: Biotest's sustainability campaign GoFuture part of the new documentary 'Future Seeds'

EQS-News: Biotest AG / Key word(s): Sustainability
Biotest's sustainability campaign GoFuture part of the new documentary 'Future Seeds'

24.06.2024 / 14:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


 

PRESS RELEASE

 

 

Biotest's sustainability campaign GoFuture part of the new documentary "Future Seeds"

 

  • Documentary shows sustainable projects from around the world and the eco-art mural "Linfa" on the Biotest campus
  • Film addresses socially relevant topic of eco-anxiety among young people
  • Now available on Prime Video in twelve countries

 

Dreieich, Germany, 24 June 2024. With its GoFuture sustainability campaign and its gigantic mural on the campus in Dreieich, Biotest AG has taken the first step with a visible signal of its growing commitment to more sustainability last year. The new documentary film "Future Seeds" now picks up on this extraordinary project and recently celebrated its premiere on Prime Video.

Future Seeds is a documentary film about innovative ideas and projects for a more sustainable future, embedded in a socially relevant and moving narrative. The film addresses the now widespread phenomenon of eco-anxiety, which manifests itself in extreme sadness, anger and despair, particularly among young people. In the film, a teenager is psychologically burdened by her fear of the consequences of climate change and is in constant discourse with her family and other adults who, in her view, do not realise the consequences of climate change or take them seriously. Her aunt, who works as a journalist, then decides to take her niece on a trip. Exciting projects from all over the world and inspiring conversations with scientists, politicians and entrepreneurs are intended to inspire her and the viewers to rethink. Due to their interest in EcoArt, the two women travel to Dreieich to visit the "Linfa" mural on the Biotest campus and talk to Biotest’s CEO, Peter Janssen, about the associated GoFuture sustainability initiative.

With this documentary, the makers want to open up a dialogue about the future of our society and address the responsibility of each individual with regard to a more sustainable future. "We are very proud to be part of this documentary with our GoFuture sustainability campaign and to be able to help give affected people new hope for a better future,” said Peter Janssen. “As a pharmaceutical company that uses donors’ blood plasma as a natural resource for drug production, we feel a tremendous responsibility towards both humanity and the environment, because the health of people is inseparable from the health of the planet.”

Future Seeds is now available in Germany, Austria, Switzerland, the United Kingdom, France, Spain, Italy, Hungary, Turkey, Canada, Australia and in the United States. The access on Prime Video and the film title vary depending on the country and language version. Access Prime Video .

 

For more information about the GoFuture campaign, visit:

 

 

About Biotest

Biotest is a provider of biological therapeutics derived from human plasma. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,400 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange. Since May 2022, Biotest has been a part of the Grifols Group, based in Barcelona, Spain ().

 

Biotest AG will now also be publishing official press releases via X. You can find us at:

 

 

IR contact

Dr Monika Baumann (Buttkereit)

Phone: 06
Mail:

 

PR contact

Dirk Neumüller

Phone: 9
Mail:

 

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany,

 

Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201

Preference shares: securities’ ID No. 522723; ISIN DE0005227235

Listing: Frankfurt (Prime Standard)

Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

 

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

 

 



24.06.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com


Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail:
Internet:
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1931603

 
End of News EQS News Service

1931603  24.06.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1931603&application_name=news&site_id=research_pool~~~9efe1c65-8ece-4ff7-9608-f21c8e0a38a3
EN
24/06/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Biotest AG Pfd

 PRESS RELEASE

EQS-News: Strategische Vereinbarung zum Vertrieb von Yimmugo® in den U...

EQS-News: Biotest AG / Schlagwort(e): Markteinführung Strategische Vereinbarung zum Vertrieb von Yimmugo® in den USA auf Grundlage des im Juli ausgehandelten Rahmenvertrags unterzeichnet 02.10.2024 / 14:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.   PRESSEMITTEILUNG     Strategische Vereinbarung zum Vertrieb von Yimmugo® in den USA auf Grundlage des im Juli ausgehandelten Rahmenvertrags unterzeichnet   Alle Vertragsbedingungen festgelegt und endgültige Vereinbarung mit Kedrion unterzeichnet Erwartetes Umsatzvolumen für ...

 PRESS RELEASE

EQS-News: Strategic agreement signed for distribution of Yimmugo® in t...

EQS-News: Biotest AG / Key word(s): Market Launch Strategic agreement signed for distribution of Yimmugo® in the United States based on the framework established in July 02.10.2024 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement.   PRESS RELEASE     Strategic agreement signed for distribution of Yimmugo® in the United States based on the framework established in July   All contractual terms finalized and definitive agreement with Kedrion signed Expected to generate revenues of more than $1 billion for Biotest during the 7-ye...

 PRESS RELEASE

EQS-News: Change in the Chief Financial Officer at Biotest AG

EQS-News: Biotest AG / Key word(s): Personnel Change in the Chief Financial Officer at Biotest AG 12.09.2024 / 15:00 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE    Change in the Chief Financial Officer at Biotest AG   Martin Möller to assume role of Chief Financial Officer (CFO) on the Management Board for 6 months starting September 14 Dreieich, Germany, September 12, 2024. The Supervisory Board of Biotest AG announced today that the former Chief Financial Officer, Ms. Ainhoa Mendizabal Zubiaga, is leaving the compan...

 PRESS RELEASE

EQS-News: Wechsel im Finanzvorstand der Biotest AG

EQS-News: Biotest AG / Schlagwort(e): Personalie Wechsel im Finanzvorstand der Biotest AG 12.09.2024 / 15:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. PRESSEMITTEILUNG   Wechsel im Finanzvorstand der Biotest AG   Martin Möller übernimmt ab 14. September für 6 Monate die Funktion des Finanzvorstands (CFO) im Vorstand   Dreieich, 12. September 2024. Der Aufsichtsrat der Biotest AG gibt heute bekannt, dass der bisherige Finanzvorstand, Frau Ainhoa Mendizabal Zubiaga, das Unternehmen aus persönlichen Gründen verlässt. Wir dan...

 PRESS RELEASE

EQS-News: Biotest AG opens 13th plasma collection center in Germany

EQS-News: Biotest AG / Key word(s): Miscellaneous Biotest AG opens 13th plasma collection center in Germany 05.09.2024 / 09:00 CET/CEST The issuer is solely responsible for the content of this announcement.     PRESS RELEASE     Biotest AG opens 13th plasma collection center in Germany   39 plasma collection centers in Europe to ensure long-term plasma supply Dreieich, Germany, September 5, 2024. Biotest has officially opened its 13th plasma collection center in Germany in Karlsruhe. In the state-of-the-art center at Europaplatz in Kaiserstrasse 146-148, plasma d...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch